|
Disease Team Planning |
Thomas Rando |
Stem Cell Therapy for Muscular Dystrophy |
$0 |
|
Transplantation Immunology |
Kenneth Weinberg |
Engineered immune tolerance by Stem Cell-derived thymic regeneration |
$1,271,729 |
|
Tools and Technologies III |
James Dunn |
Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$772,098 |
|
Tools and Technologies II |
Brian Rutt |
Development of Single Cell MRI Technology using Genetically-Encoded Iron-Based Reporters |
$1,833,348 |
|
Clinical Trial Stage Projects |
Judith Shizuru |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$1,113,487 |
|
Disease Team Therapy Planning I |
Judith Shizuru |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$90,147 |
|
Clinical Trial Stage Projects |
Joseph Wu |
A Phase I, Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes in PaTients with ChrOnic Ischemic Left VentRicular Dysfunction (HECTOR) |
$6,987,507 |
|
Disease Team Therapy Development - Research |
Joseph Wu |
Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$19,060,330 |
|
Quest - Discovery Stage Research Projects |
Sarah Heilshorn |
Injectable, autologous iPSC-based therapy for spinal cord injury |
$789,000 |
|
Creativity Awards |
Paul Utz |
SIMR Program: Stem Cell & Developmental Biology Research Internships |
$340,611 |
|
Basic Biology V |
Xinnan Wang |
Misregulated Mitophagy in Parkinsonian Neurodegeneration |
$1,174,943 |
|
Basic Biology I |
Susan McConnell |
Identification and characterization of human ES-derived DA neuronal subtypes |
$1,404,853 |
|
Tools and Technologies III |
Anthony Oro |
A Chromatin Context Tool for Predicting iPS Lineage Predisposition and Tissue Graftability |
$1,391,125 |
|
Disease Team Research I |
Gary Steinberg |
Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke |
$17,244,851 |
|
Conference II |
Joseph Wu |
Drug Discovery & Stem Cell Models for Cardiovascular Disease Conference |
$7,500 |
|
SEED Grant |
John Cooke |
EC regeneration in cerebrovascular ischemia: role of NO |
$476,995 |
|
Quest - Discovery Stage Research Projects |
Matthew Porteus |
Genome Editing to Correct Cystic Fibrosis Mutations in Airway Stem Cells |
$1,968,456 |
|
SEED Grant |
Mark Kay |
Novel vectors for gene transfer into human ES cells |
$574,737 |
|
Clinical Trial Stage Projects |
Robert Lowsky |
Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors |
$6,653,266 |
|
Comprehensive Grant |
Christopher Zarins |
Engineering a Cardiovascular Tissue Graft from Human Embryonic Stem Cells |
$2,454,490 |
|
Late Stage Preclinical Projects |
Matthew Porteus |
Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease |
$4,849,363 |
|
New Faculty I |
Anne Brunet |
Molecular mechanisms involved in adult neural stem cell maintenance |
$2,348,435 |
|
Clinical Trial Stage Projects |
David Miklos |
Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies |
$11,034,982 |
|
Tools and Technologies II |
Irving Weissman |
Antibody tools to deplete or isolate teratogenic, cardiac, and blood stem cells from hESCs |
$1,463,814 |
|
Late Stage Preclinical Projects |
Rosa Bacchetta |
IND-enabling activities for a Phase 1 Study of Autologous CD4LVFOXP3 T Cells in Subjects with IPEX Syndrome |
$5,002,496 |
|
Disease Team Therapy Planning I |
Albert Wong |
Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma |
$109,750 |
|
Quest - Discovery Stage Research Projects |
Kathleen Sakamoto |
Small Molecules to inhibit Nemo-like Kinase for Treatment of Diamond Blackfan Anemia |
$848,098 |
|
Basic Biology IV |
Howard Chang |
Long noncoding RNAs for pluripotency and cell fate commitment |
$1,386,627 |
|
Quest - Discovery Stage Research Projects |
Bertha Chen |
iPSC-derived smooth muscle cell progenitor conditioned medium for treatment of pelvic organ prolapse |
$1,420,200 |
|
New Faculty Physician Scientist |
Alan Cheng |
Enhancing hair cell regeneration in mouse and human inner ear |
$3,088,525 |
|
Basic Biology V |
Helen Blau |
Mass Cytometry to Delineate the Human Muscle Stem Cell Hierarchy and Dysfunction in Aging |
$1,175,357 |
|
Basic Biology I |
Julien Sage |
The retinoblastoma (RB) gene family in cellular reprogramming |
$1,357,085 |
|
Tools and Technologies III |
Fan Yang |
Injectable Macroporous Matrices to Enhance Stem Cell Engraftment and Survival |
$1,434,235 |
|
Disease Team Research I |
Irving Weissman |
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$18,759,276 |
|
Inception - Discovery Stage Research Projects |
Phillip Yang |
Activation of patient-specific endogenous myocardial repair through the exosomes generated from the hypoxic iPSC-derived cardiomyocytes (iCMs). |
$234,619 |
|
SEED Grant |
Aaron Hsueh |
Patient-specific cells with nuclear transfer |
$629,653 |
|
Conference |
Julien Sage |
3rd International RB conference |
$10,000 |
|
SEED Grant |
Julien Sage |
Functions of RB family proteins in human embryonic stem cells |
$498,609 |
|
Comprehensive Grant |
Renee Reijo Pera |
Human oocyte development for genetic, pharmacological and reprogramming applications |
$2,298,411 |
|
New Faculty I |
Howard Chang |
Noncoding RNAs in Cell Fate Determination |
$2,985,894 |
|
Tools and Technologies II |
Marius Wernig |
Cellular tools to study brain diseases affecting synaptic transmission |
$1,664,382 |
|
Disease Team Therapy Planning I |
Robert Robbins |
Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$73,030 |
|
Quest - Discovery Stage Research Projects |
Phillip Yang |
Hypoxia-specific Production of Exosomes from iPSC-derivatives for Myocardial Repair |
$1,418,023 |
|
Basic Biology IV |
Gerald Crabtree |
Mechanism and Utility of Direct Neuronal Conversion with a MicroRNA-Chromatin Switch |
$1,392,150 |
|
Quest - Discovery Stage Research Projects |
Ansuman Satpathy |
Preclinical development of an exhaustion-resistant CAR-T stem cell for cancer immunotherapy |
$1,420,200 |
|
New Faculty Physician Scientist |
Michelle Monje |
White matter neuroregeneration after chemotherapy: stem cell therapy for “chemobrain” |
$2,800,526 |
|
Basic Biology V |
Marius Wernig |
Mechanisms of human induced neuronal cell reprogramming |
$1,178,370 |
|
Basic Biology I |
Helen Blau |
Molecular Mechanisms of Reprogramming towards Pluripotency |
$1,408,332 |
|
Tools and Technologies III |
Sarah Heilshorn |
Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System |
$1,347,767 |
|
New Cell Lines |
Julie Baker |
Derivation of hESC Lines with Disease Lesions |
$1,404,725 |
|
Inception - Discovery Stage Research Projects |
Bertha Chen |
Autologous iPSC-based therapy for radiation induced bladder injury |
$235,836 |
|
SEED Grant |
Thomas Wandless |
Reprogramming Differentiated Human Cells to a Pluripotent State |
$380,005 |
|
Conference |
Thomas Rando |
Third Annual Symposium on Regenerative Rehabilitation |
$20,000 |
|
New Faculty II |
Ching-Pin Chang |
VEGF signaling in adventitial stem cells in vascular physiology and disease |
$3,005,695 |
|
Conference II |
Joseph Wu |
2017 Stanford Drug Discovery and Stem Cell Technology Conference |
$2,359 |
|
Early Translational I |
Jill Helms |
Enhancing healing via Wnt-protein mediated activation of endogenous stem cells |
$6,464,126 |
|
Inception - Discovery Stage Research Projects |
Guillem Pratx |
Novel metabolic labeling method for tracking stem cells to irradiated salivary glands using PET |
$229,227 |
|
New Faculty I |
Karl Deisseroth |
Bioengineering technology for fast optical control of differentiation and function in stem cells and stem cell progeny |
$2,424,209 |
|
Quest - Discovery Stage Research Projects |
Katja Weinacht |
Regenerative Thymic Tissues as Curative Cell Therapy for Patients with 22q11 Deletion Syndrome |
$1,251,720 |
|
Basic Biology III |
Michael Clarke |
USP16 controls stem cell number: implications for Down Syndrome |
$1,263,826 |
|
Discovery Research Projects |
Helen Blau |
Application of PGE2/BPV, a muscle stem cell targeting therapeutic, to the treatment of COVID-19 associated diaphragm atrophy |
$149,996 |
|
Training Grant I-1 |
Michael Longaker |
Stanford CIRM Training Program |
$3,035,282 |
|
Quest - Discovery Stage Research Projects |
Marius Wernig |
A universally applicable skin sheet for Dystrophic Epidermolysis Bullosa via next-generation gene editing, iPS cell technology and tissue engineering |
$1,229,040 |
|
Basic Biology IV |
Roel Nusse |
Asymmetric stem cell division oriented by a local self-renewing signal |
$1,038,600 |
|
Clinical Trial Stage Projects |
Rosa Bacchetta |
Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome |
$11,999,179 |
|
Tissue Collection for Disease Modeling |
Joachim Hallmayer |
Induced pluripotent stem cells from children with autism spectrum disorders |
$530,265 |
|
Basic Biology V |
Gary Steinberg |
Paracrine and synaptic mechanisms underlying neural stem cell-mediated stroke recovery |
$1,178,370 |
|
Basic Biology II |
Steven Artandi |
Self-renewal and senescence in iPS cells derived from patients with a stem cell disease |
$931,285 |
|
Tools and Technologies III |
Irving Weissman |
Identification and isolation of transplantable human hematopoietic stem cells from pluripotent cell lines; two steps from primitive hematopoiesis to transplantable definitive cells, and non-toxic conditioning of hosts for hematopoeitic stem cell transp... |
$1,271,952 |
|
New Cell Lines |
Michele Calos |
Safe, efficient creation of human induced pluripotent stem cells without the use of retroviruses |
$1,406,875 |
|
Inception - Discovery Stage Research Projects |
Philip Beachy |
Curing bladder cancer by replacing corrupted urothelium with differentiated hES cells |
$210,906 |
|
SEED Grant |
Kenneth Weinberg |
Embryonic stem cell-derived thymic epithelial cells |
$628,793 |
|
Conference |
Fan Yang |
2014 Materials Research Society (MRS) Spring Meeting:
Symposium Y: Biomaterials for Biomolecule Delivery and Understanding Cell-Niche Interactions |
$10,000 |
|
Comprehensive Grant |
Irving Weissman |
Prospective isolation of hESC-derived hematopoietic and cardiomyocyte stem cells |
$2,471,386 |
|
Patent Assistance Fund Awards |
Katharine Ku |
Funding for Patent Applications for CIRM-funded Inventions out of Stanford University |
$3,525 |
|
Shared Labs |
Vittorio Sebastiano |
The Stanford University Center for Human Embryonic Stem Cell Research and Education |
$3,434,600 |
|
Tools and Technologies I |
Helen Blau |
Regulation of Stem Cell Fate in Bioengineered Arrays of Hydrogel Microwells |
$949,608 |
|
Inception - Discovery Stage Research Projects |
Hiromitsu Nakauchi |
Optimizing self-renewal signaling kinetics to stabilize ex vivo hematopoietic stem cell expansion |
$210,906 |
|
New Faculty I |
Joanna Wysocka |
Trithorax and Polycomb methyltransferase complexes in cell fate determination. |
$2,373,903 |
|
Quest - Discovery Stage Research Projects |
Philip Beachy |
Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer |
$1,265,436 |
|
Basic Biology III |
Aaron Hsueh |
Correlated time-lapse imaging and single cell molecular analysis of human embryo development |
$1,259,733 |
|
Discovery Research Projects |
Albert Wong |
Identifying HLA Class I Restricted Peptides That Induce CD8+ T Cells Against SARS-CoV-2 |
$249,999 |
|
Early Translational III |
Joseph Wu |
Heart Repair with Human Tissue Engineered Myocardium |
$4,395,080 |
|
Quest - Discovery Stage Research Projects |
Stanley Qi |
A novel hybrid CRISPR tool for gene network perturbation and hiPSC engineering |
$704,661 |
|
Basic Biology IV |
Anne Brunet |
Energy metabolism and aging pathways in human stem cell reprogramming and differentiation |
$1,414,044 |
|
Conference II |
Joseph Wu |
Stanford Drug Discovery Symposium 2022 |
$29,408 |
|
Tissue Collection for Disease Modeling |
Joseph Wu |
Tissue Collection for Accelerating iPSC Research in Cardiovascular Diseases |
$1,291,832 |
|
Major Facilities |
John Hennessy |
Stanford SIM1 Building |
$43,578,000 |
|
Basic Biology II |
Garry Nolan |
Kinase signaling analysis of iPS cell reprogramming and differentiation |
$1,343,100 |
|
Tools and Technologies III |
Joseph Wu |
Macaca mulatta as advanced model for predictive preclinical testing of engineered cardiac autografts and allografts |
$1,689,744 |
|
New Cell Lines |
Michael Longaker |
Derivation and analysis of pluripotent stem cell lines with inherited TGF-b mediated disorders from donated IVF embryos and reprogrammed adult skin fibroblasts |
$1,406,636 |
|
Inception - Discovery Stage Research Projects |
Jeffrey Goldberg |
Embryonic Stem Cells for Corneal Endothelial Degeneration |
$235,836 |
|
SEED Grant |
Joseph Wu |
In Vivo Imaging of Human Embryonic Stem Cell Derivatives and Tumorigenicity |
$623,634 |
|
Conference |
Joseph Wu |
Cardiovascular Regenerative Medicine Symposium |
$9,000 |
|
Comprehensive Grant |
Stefan Heller |
Generation of inner ear sensory cells from human ES cells toward a cure for deafness |
$2,330,371 |
|
Inception - Discovery Stage Research Projects |
Helen Blau |
Prodrug innovation to target muscle stem cells and enhance muscle regeneration |
$235,834 |
|
Transplantation Immunology |
Christopher Contag |
Engineering Embryonic Stem Cell Allografts for Operational Tolerance |
$1,411,338 |
|
Quest - Discovery Stage Research Projects |
Helen Blau |
Stimulating endogenous muscle stem cells to counter muscle atrophy |
$2,198,687 |
|
Tools and Technologies II |
Michele Calos |
Site-specific integration of Lmx1a, FoxA2, & Otx2 to optimize dopaminergic differentiation |
$1,592,897 |
|
Quest - Discovery Stage Research Projects |
Alan Cheng |
Modulation of the Wnt pathway to restore inner ear function |
$1,389,416 |
|
Basic Biology III |
Joanna Wysocka |
Enhancer-mediated gene regulation during early human embryonic development |
$1,420,618 |
|
Early Translational III |
Helen Blau |
Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients |
$1,825,283 |
|
Clinical Trial Stage Projects |
Maria Grazia Roncarolo |
Phase 1/1b study of T-allo10 infusion after HLA-partially matched abdepleted-HSCT in children and young adults with hematologic malignancies. |
$10,563,822 |
|
Basic Biology IV |
Michael Cleary |
Prostaglandin pathway regulation of self-renwal in hematopoietic and leukemia stem cells |
$1,244,455 |
|
Quest - Discovery Stage Research Projects |
Judith Shizuru |
Targeted Immunotherapy-Based Blood Stem Cell Transplantation |
$1,341,910 |
|
Early Translational IV |
Michele Calos |
Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B |
$1,876,253 |
|
Disease Team Planning |
Robert Robbins |
{REDACTED} Cardiovascular Regenerative Team |
$25,119 |
|
Basic Biology II |
Aaron Hsueh |
Maturation of Human Oocytes for SCNT and Embryonic Stem Cell Derivation |
$1,309,018 |
|
Preclinical Development Awards |
Matthew Porteus |
Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 |
$874,877 |
|
New Cell Lines |
Renee Reijo Pera |
Derivation and comparative analysis of human pluripotent ESCs, iPSCs and SSCs: Convergence to an embryonic phenotype |
$1,409,243 |
|
Quest - Discovery Stage Research Projects |
Hiromitsu Nakauchi |
Novel Rejuvenated T Cell Immunotherapy for Lung Cancer |
$1,968,456 |
|
SEED Grant |
Joanna Wysocka |
Role of Chromatin Modifiers in Regulating Human Embryonic Stem Cell Pluripotency |
$629,952 |
|
Conference |
Thomas Rando |
Keystone Symposia, 'The Life of a Stem Cell: From Birth to Death' |
$50,000 |
|
Comprehensive Grant |
Roel Nusse |
Guiding the developmental program of human embryonic stem cells by isolated Wnt factors |
$1,710,462 |
|
Quest - Discovery Stage Research Projects |
Mark Mercola |
Multipotent Cardiovascular Progenitor Regeneration of the Myocardium after MI |
$1,809,234 |
|
Conference II |
Samuel Strober |
Third International Workshop on Clinical Tolerance |
$29,500 |
|
Transplantation Immunology |
Robert Negrin |
Regulatory T cell induced tolerance to ESC transplantation |
$1,382,658 |
|
Quest - Discovery Stage Research Projects |
Kyle Loh |
Towards hepatocyte cell replacement therapy: developing a renewable source of human hepatocytes from pluripotent stem cells |
$1,968,456 |
|
Tools and Technologies II |
Theo Palmer |
Development of small molecule screens for autism using patient-derived iPS cells |
$1,797,606 |
|
Basic Biology III |
Sean Wu |
Elucidating Molecular Basis of Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells |
$1,260,537 |
|
Clinical Trial Stage Projects |
Gary Steinberg |
Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects with Chronic Ischemic Subcortical Stroke |
$11,998,988 |
|
Early Translational III |
Bertha Chen |
Autologous iPSC Therapy for Urinary Incontinence |
$4,715,738 |
|
Research Training Grant |
Michael Longaker |
CIRM Scholar Training Program |
$4,974,073 |
|
Basic Biology IV |
Alexander Dunn |
Role of mechanical signaling in stem cell self-renewal and differentiation |
$1,062,998 |
|
Foundation - Discovery Stage Research Projects |
Marius Wernig |
Developing a microglia replacement therapy |
$1,577,979 |
|
Disease Team Therapy Development III |
Irving Weissman |
Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors |
$6,505,568 |
|
Shared Labs |
Renee Reijo Pera |
The Stanford University Center for Human Embryonic Stem Cell Research and Education |
$2,439,590 |
|
Early Translational II |
Michele Calos |
Stem Cell Therapy for Duchenne Muscular Dystrophy |
$2,267,261 |
|
SPARK |
Paul Utz |
Stem Cell and Regenerative Medicine- Summer Research Internship |
$350,482 |
|
SEED Grant |
Krishna Shenoy |
Technology for hESC-Derived Cardiomyocyte Differentiation and Optimization of Graft-Host Integration in Adult Myocardium |
$572,891 |
|
Quest - Discovery Stage Research Projects |
Rosa Bacchetta |
GENE EDITING FOR FOXP3 IN HUMAN HSC |
$984,228 |
|
SEED Grant |
Phillip Yang |
In Vivo Molecular Magnetic Resonance Imaging of Human Embryonic Stem Cells in Murine Model of Myocardial Infarction |
$629,952 |
|
Conference |
Hank Greely |
Stem Cell Policy: Understanding the Scientific and Legal Challenges Ahead |
$5,838 |
|
Comprehensive Grant |
Julie Baker |
Functional Genomic Analysis of Chemically Defined Human Embryonic Stem Cells |
$2,518,303 |
|
Late Stage Preclinical Projects |
Gary Steinberg |
Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke |
$5,300,000 |
|
Transplantation Immunology |
Judith Shizuru |
Purified allogeneic hematopoietic stem cells as a platform for tolerance induction |
$1,233,275 |
|
Conference II |
Joseph Wu |
2018 Stanford Drug Discovery and Stem Cell Technology Conference |
$15,000 |
|
Tools and Technologies II |
Sarah Heilshorn |
Preparation and Delivery of Clinically Relevant Numbers of Stem Cells Using 3D Hydrogels |
$600,695 |
|
Clinical Trial Stage Projects |
Everett Meyer |
Induction of Tolerance by Combinatorial Therapy w/ Donor Stem Cells and Expanded Recipient Treg cells in HLA-mismatched Kidney Transplant Recipients |
$11,955,585 |
|
Research Training II |
Theo Palmer |
Stanford CIRM Training Program |
$7,017,629 |
|
Clinical Trial Stage Projects |
Crystal Mackall |
Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor T Cells for Diffuse Intrinsic Pontine Gliomas and Spinal Diffuse Midline Glioma |
$11,998,310 |
|
Disease Team Therapy Development - Research |
Judith Shizuru |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$18,990,683 |
|
SPARK |
Paul Utz |
Stem Cell and Regenerative Medicine- High School Summer Research Internship |
$508,750 |
|
Basic Biology IV |
Michelle Monje |
Stem Cell Mechanisms Governing Discrete Waves of Gliogenesis in the Childhood Brain |
$1,264,248 |
|
Research Leadership |
Hiromitsu Nakauchi |
Generation of functional cells and organs from iPSCs |
$5,426,135 |
|
Genomics Centers of Excellence Awards (R) |
Michael Snyder |
Center of Excellence for Stem Cell Genomics - Stanford |
$22,787,914 |
|
Disease Team Research I |
Alfred Lane |
iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa |
$11,039,208 |
|
SEED Grant |
Calvin Kuo |
Differentiation of Human Embryonic Stem Cells to Intestinal Fates |
$554,176 |
|
Quest - Discovery Stage Research Projects |
Roel Nusse |
Preclinical development of human hepatocyte progenitor cells for cell therapy |
$1,651,211 |
|
SEED Grant |
Susan McConnell |
Optimization of guidance response in human embryonic stem cell derived midbrain dopaminergic neurons in development and disease |
$607,363 |
|
Conference |
Joseph Wu |
Cardiovascular Tissue Engineering Symposium |
$25,000 |
|
Comprehensive Grant |
Theo Palmer |
Immunology of neural stem cell fate and function |
$2,396,000 |
|
Progression Award - Discovery Stage Research Projects |
Hiromitsu Nakauchi |
Using metabolic pausing for maintaining stable and high-quality pluripotent stem cells |
$208,422 |
|
Progression Award - Discovery Stage Research Projects |
Helen Blau |
Stimulating endogenous muscle stem cells to counter muscle wasting |
$237,060 |
|
Tool Translational Research Projects |
Joseph Wu |
A Novel, Robust and Comprehensive Predictive Tool Using Human Disease-Specific Induced Pluripotent Stem Cells for Preclinical Drug Screening |
$975,000 |
|
Therapeutic Translational Research Projects |
Anthony Oro |
DEBCT: Genetically Corrected, Induced Pluripotent Cell-Derived Epithelial Sheets for Definitive Treatment of Dystrophic Epidermolysis Bullosa |
$5,107,353 |
|
Therapeutic Translational Research Projects |
Bertha Chen |
Autologous iPSC-derived smooth muscle cell therapy for treatment of urinary incontinence |
$5,977,155 |
|
Therapeutic Translational Research Projects |
Theodore Leng |
NeuBright, a purified allogeneic cell therapy product for treatment of Dry Age-related Macular Degeneration |
$4,235,758 |
|
Therapeutic Translational Research Projects |
Albert Wong |
2nd Generation Vaccine for the Treatment of Glioblastoma |
$2,929,889 |
